Mar 8 |
Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript
|
Mar 8 |
Bio-Path reports FY results
|
Mar 8 |
Bio-Path Holdings Reports Full Year 2023 Financial Results
|
Mar 8 |
Earnings Scheduled For March 8, 2024
|
Mar 7 |
Bio-Path Holdings's Earnings: A Preview
|
Mar 1 |
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
|
Feb 17 |
When Can We Expect A Profit From Bio-Path Holdings, Inc. (NASDAQ:BPTH)?
|
Jan 10 |
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
|
Dec 14 |
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
|